SSB signs distribution deal for endonuclease  

Sartorius Stedim Biotech (SSB) has signed a worldwide sales and distribution agreement for c-LEcta’s proprietary Serratia marcescens nuclease for biopharmaceutical applications. The customised endonuclease is available under the product name Denarase through all regular SSB sales channels.

c-LEcta has optimised the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins.

“This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance,”said Dr. Uwe Gottschalk, VicePresident of Purification Technologies at Sartorius Stedim Biotech.

“The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total

solution provider for the biopharmaceutical industry.”

Dr. Marc Struhalla, Managing Director of c-LEcta added: “The technology developed by

c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialisation of our product.”